GlassScriptPhysician profile
Michael S Lifshen
NPI 1982605234
$12,038.98
in general payments reported to CMS, 2019-2025
57 companies · $1,843 in 2025
The $1,843 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,340 · 2020: $1,405 · 2021: $1,510 · 2022: $1,378 · 2023: $1,785 · 2024: $1,777 · 2025: $1,843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,405.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,374.17 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,220.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,021.29 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $920.45 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $707.26 | 2019-2025 | |
| Amgen INC. | $647.60 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $548.25 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $470.71 | 2019-2025 | Unithroid |
| Takeda Pharmaceuticals U.S.A., INC. | $458.79 | 2019-2025 | Trintellix |
| Antares Pharma, INC. | $436.03 | 2020-2025 | Xyosted, Tlando, Nocdurna |
| Amarin Pharma, INC. | $384.17 | 2019-2022 | |
| Gilead Sciences, INC. | $359.52 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $254.56 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $239.87 | 2019-2025 | Xifaxan |
| Allergan, INC. | $238.27 | 2019-2020 |
Show all 56 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lifshen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.